EGFR and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), exosomal AREG increases the expression of RANKL, which subsequently increases the expression of osteoclastogenesis markers in pre-osteoclast by activating the EGFR pathway, promoting osteolytic bone metastasis (64).